Merck FAKED mumps vaccine research, released faulty vaccine

New Post Public Reply Private Reply Replies (0) Message Board
Lmcat
415
Merck FAKED mumps vaccine research, released faulty vaccine that didn’t work, say virologists in False Claims Act filing

Woman-Science-Test-Vaccine-Vials-Dropper-678x381.jpg

With the deceptive “mainstream” media now running measles hysteria 24/7, you might be shocked to learn that the MMR vaccine doesn’t work as claimed.

Even Reuters is now reporting that 10% of those infected with the measles were previously vaccinated against the measles.

This stunning admission is found in an April 29 article from Reuters entitled, “U.S. measles outbreak raises questions about immunity in adults.” The article states:

Up to 10 percent of the 695 confirmed measles cases in the current outbreak occurred in people who received one or two doses of the vaccine, according to the U.S. Centers for Disease Control and Prevention.

Merck FAKED vaccine efficacy data and committed widespread scientific fraud, say virologists

If you’re wondering why so many people who were vaccinated against measles, mumps and rubella are now being infected with the measles, you have to remember that Merck faked its MMR vaccine efficacy data by spiking human blood samples with animal antibodies, according to two former Merck employees who say they were ordered by Merck management to carry out the massive science fraud.

The two Merck virologists, named Stephen Krahling and Joan Wlochowski, filed a False Claims Act document in 2010 that specifically called out Merck’s fraudulent vaccine deception as running the risk of contributing the future outbreaks of infectious disease.

That’s exactly what we’re seeing today, of course, with measles spreading across America, even among those who were previously vaccinated against measles. (Because the vaccine doesn’t work, get it?)

Natural News originally covered this story in 2012, and we preserved the original False Claims Act document at the following link, making sure it wasn’t memory-holed off the internet:

https://www.naturalnews.com/gallery/documents...ms-Act.pdf

Merck vaccine fraud exposed by two Merck virologists; company faked mumps vaccine efficacy results for over a decade, says lawsuit

According to two Merck scientists who filed a False Claims Act complaint in 2010 — a complaint which has just now been unsealed — vaccine manufacturer Merck knowingly falsified its mumps vaccine test data, spiked blood samples with animal antibodies, sold a vaccine that actually promoted mumps and measles outbreaks, and ripped off governments and consumers who bought the vaccine thinking it was “95% effective.”


See that False Claims Act document at:
https://www.naturalnews.com/gallery/documents...ms-Act.pdf

According to Stephen Krahling and Joan Wlochowski, both former Merck virologists, the Merck company engaged in all the following behavior:

• Merck knowingly falsified its mumps vaccine test results to fabricate a “95% efficacy rate.”


• In order to do this, Merck spiked the blood test with animal antibodies in order to artificially inflate the appearance of immune system antibodies. As reported in CourthouseNews.com:

Merck also added animal antibodies to blood samples to achieve more favorable test results, though it knew that the human immune system would never produce such antibodies, and that the antibodies created a laboratory testing scenario that “did not in any way correspond to, correlate with, or represent real life … virus neutralization in vaccinated people,” according to the complaint. (http://www.courthousenews.com/2012/06/27/478…)

• Merck then used the falsified trial results to swindle the U.S. government out of “hundreds of millions of dollars for a vaccine that does not provide adequate immunization.”

• Merck’s vaccine fraud has actually contributed to the continuation of mumps across America, causing more children to become infected with mumps.
(Gee, really? This is what NaturalNews has been reporting for years… vaccines are actually formulated to keep the outbreaks going because it’s great for repeat business!)

• Merck used its false claims of “95 percent effectiveness” to monopolize the vaccine market and eliminate possible competitors.

• The Merck vaccine fraud has been going on since the late 1990’s, say the Merck virologists.

• Testing of Merck’s vaccine was never done against “real-world” mumps viruses in the wild. Instead, test results were simply falsified to achieve the desired outcome.

• This entire fraud took place “with the knowledge, authority and approval of Merck’s senior management.”


• Merck scientists “witnessed firsthand the improper testing and data falsification in which Merck engaged to artificially inflate the vaccine’s efficacy findings,” according to court documents (see below).

US government chose to ignore the 2010 False Claims Act!

Rather than taking action on this false claims act, the U.S. government simply ignored it, thereby protecting Merck’s market monopoly instead of properly serving justice. This demonstrates the conspiracy of fraud between the U.S. government, FDA regulators and the vaccine industry.
Chatom Primary Care sues Merck for Sherman Act monopolization, breach of warranty, violation of consumer protection laws

Following the unsealing of this 2010 False Claims Act, Chatom Primary Care, based in Alabama, smelled something rotten. Three days ago, Chatom filed a lawsuit against Merck. That lawsuit record is available here:
www.naturalnews.com/gallery/documents/Chatom…

It alleges, among other shocking things:

[Merck engaged in] …a decade-long scheme to falsify and misrepresent the true efficacy of its vaccine.

Merck fraudulently represented and continues to falsely represent in its labeling and elsewhere that its Mumps Vaccine has an efficacy rate of 95 percent of higher.

In reality, Merck knows and has taken affirmative steps to conceal — by using improper testing techniques and falsifying test data — that its Mumps Vaccine is, and has been since at least 1999, far less than 95 percent effective.

Merck designed a testing methodology that evaluated its vaccine against a less virulent strain of the mumps virus. After the results failed to yield Merck’s desired efficacy, Merck abandoned the methodology and concealed the study’s findings.

…incorporating the use of animal antibodies to artificially inflate the results…

…destroying evidence of the falsified data and then lying to an FDA investigator…

…threatened a virologist in Merck’s vaccine division with jail if he reported the fraud to the FDA…


…the ultimate victims here are the millions of children who every year are being injected with a mumps vaccine that is not providing them with an adequate level of protection.

And while this is a disease that, according to the Centers for Disease Control (‘CDC’), was supposed to be eradicated by now, the failure in Merck’s vaccine has allowed this disease to linger, with significant outbreaks continuing to occur.

Chatom Primary Care also alleges that the fraudulent Merck vaccine contributed to the 2006 mumps outbreak in the Midwest, and a 2009 outbreak elsewhere. It says, “there has remained a significant risk of a resurgence of mumps outbreaks…”

This investigation is only beginning

NaturalNews has only begun to investigate this incredible breaking news about Merck and the vaccine industry. We are pouring through the court documents to identify additional information that may be relevant to this case, and we plan to bring you that information soon.

For the record, Merck denies all allegations. Is anyone surprised?


Sources for this article:
NaturalNews wishes to thank CourthouseNews.com for its coverage of this story. Original article at: http://www.courthousenews.com/2012/06/27/478…

Chatom Lawsuit against Merck
www.naturalnews.com/gallery/documents/Chatom…

2010 False Claims Act against Merck, by two Merck virologists
www.naturalnews.com/gallery/documents/Merck-…

https://www.dcclothesline.com/2019/05/02/merc...ct-filing/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 352

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 204

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 176

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 214

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 197

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 0

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 337

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 37

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 138

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Power Generation System from Pipeline Flow Unveiled

Updated Category News Views 231

Revolutionizing Energy Generation from Pipelines Innovators are always seeking new ways to deliver sustainable energy solutions, and one recent idea has emerged that may change the way we think about power generation. An inventive thinker has designed a technology that utilizes pipelines, specifically those carrying fluid or gas, to generate electricity. This innovative...

Continue Reading
Elliott Hill Takes Helm at Nike: A Step Toward Retail Revival

Updated Category News Views 276

Elliott Hill Takes Charge at Nike Nike Inc. (NYSE: NKE) has appointed Elliott Hill as its new CEO. This decision aims to strengthen the brand's connections with retail partners and enhance sales efforts. What Led to the Change? Hill steps into this important role following the departure of John Donahoe, who implemented a direct-to-consumer sales model. While this approach...

Continue Reading
ImageneBio Completes Merger with Ikena Oncology and Raises Capital

Updated Category News Views 249

ImageneBio's New Era Begins with Merger and Funding Boost The merger between Inmagene Biopharmaceuticals and Ikena Oncology marks a significant milestone as the newly formed company, ImageneBio, Inc., is set to make its debut on Nasdaq with the ticker symbol ‘IMA’. This exciting transition underlines the commitment of ImageneBio to further develop innovative...

Continue Reading
Equity Lifestyle Properties: Insights Ahead of Earnings Report

Updated Category News Views 168

Equity Lifestyle Properties' Earnings Expectations Equity Lifestyle Properties (ELS) is preparing for an upcoming quarterly earnings announcement that is highly anticipated by investors. This release is set to provide crucial insights into the company's financial health and projections for future growth. Analyst Predictions for Earnings Experts in the field forecast that...

Continue Reading
NexPoint Advocates for UDF IV Shareholders Amid Acquisition Talks

Updated Category News Views 119

NexPoint Advocates for UDF IV Shareholders Amid Acquisition Talks NexPoint Real Estate Opportunities, LLC, along with its affiliates, has expressed its thoughts regarding the proposed acquisition of United Development Funding IV (UDF IV) by Ready Capital Corporation. This transaction highlights NexPoint's continued commitment to impacting shareholder value. Transaction...

Continue Reading